<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058029</url>
  </required_header>
  <id_info>
    <org_study_id>GS-200-002</org_study_id>
    <nct_id>NCT03058029</nct_id>
  </id_info>
  <brief_title>Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects With Prediabetes and With and Without Type 2 Diabetes</brief_title>
  <acronym>LIGHT-UP</acronym>
  <official_title>A Randomize, Double-blind, Placebo-controlled, Parallel-group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects With Prediabetes and With or Without Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelesis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelesis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of
      Gelesis200 on Body Weight in Overweight and Obese Subjects without or with Type 2 Diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of
      Gelesis200 on Body Weight in Overweight and Obese Subjects without or with Type 2 Diabetes
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight (percent change)</measure>
    <time_frame>Up to 31 weeks</time_frame>
    <description>Placebo-adjusted weight loss of ≥3.0% from baseline up to 31 weeks in prediabetic subjects or ≥2.0% in diabetic subjects on Gelesis200.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight responders (≥5.0% weight loss)</measure>
    <time_frame>Up to 31 weeks</time_frame>
    <description>Weight loss of &gt;5.0% in at least 35% of prediabetic subjects or in at least 25% of diabetic subjects on Gelesis200.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with change in HbA1c status (normal, impaired, or diabetic)</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with change in FPG status (normal, impaired, or diabetic)</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with change in post-OGTT plasma glucose status (normal, impaired, or diabetic)</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change or percent change in post-OGTT plasma glucose</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change or percent change in post-OGTT serum insulin AUC</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum insulin</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Gelesis200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gelesis200: Three (3) Gelesis200 capsules (2.10 gram (g)) two (2) times per day (id est (i.e.), lunch and dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Three (3) placebo capsules two (2) times per day (i.e., lunch and dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelesis200</intervention_name>
    <description>Subject would take active Glesis200 capsules 3 times per day.</description>
    <arm_group_label>Gelesis200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subject would take placebo capsules 3 times per day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female ambulatory subjects Age ≥22 years and ≤65 years Body Mass Index (BMI) ≥27
        and ≤40 kilogram (kg)/meter (M)2

        Non-diabetic subjects,including:

          1. Normoglycemic subjects with FPG ≥90 milligram (mg)/deciliter (dL) and &lt;100 mg/dL
             [≥5.0millimole (mmol)/liter (L) and &lt;5.6 mmol/L] at both Screening Visits with HbA1c
             &lt;5.7% (&lt;39 mmol/mol), or

          2. Prediabetic subjects with FPG≥100 mg/dL and &lt;126mg/dL [≥5.6 millimole (mmol)/liter (L)
             and &lt;7.0mmol/L] at both Screening Visits with HbA1c ≤6.4%[≤46 mmol/mole (mol)][if only
             one (1)value is within this range, the other value should not be ≥126mg/dL
             (≥7.0mmol/L) and HbA1c should be ≥5.7% (≥39 mmol/mol) and ≤6.4%(≤46 mmol/mol)]

        or Diabetic subjects, including:

          1. Untreated subjects with FPG ≤200 mg/dL (≤11.2 mmol/L)at both Screening Visits and
             either FPG ≥126 mg/dL (≥7.0 mmol/L) at both Screening Visits or FPG &lt;126 mg/dL (&lt;7.0
             mmol/L) at one (1) or both Screening Visits with HbA1c ≥6.5% (≥48 mmol/mol), or

          2. Drug-treated subjects with metformin and/or dipeptidyl peptidase-4 (DPP-4)inhibitors
             with FPG ≥70 mg/dL and ≤270 mg/dL (≥3.9 mmol/L and ≤15.1 mmol/L) at both Screening
             Visits

        Fasting serum insulin &lt;24 microunit (µU)/milliliter (mL)at both Screening Visits in
        normoglycemic subjects Ability to follow verbal and written instructions Consent obtained
        via signed ICF

        Exclusion Criteria:

        Pregnancy [or positive serum or urine pregnancy test(s) in females of childbearing
        potential] Absence of medically approved contraception in females of childbearing
        potential[exempli gratia (e.g.), hysterectomy, oral contraceptive medications,intrauterine
        device combined with a barrier method, two (2) combined barrier methods such as diaphragm
        and condom or spermicide, or condom and spermicide; bilateral tubal ligation and vasectomy
        are acceptable contraceptive methods when combined with another single method from above]
        History of allergic reaction to carboxymethylcellulose(CMC), citric acid, maltodextrin,
        gelatin, ortitanium dioxide Participation in a weight loss study within the past six (6)
        months Administration of Prototype 2 (GSP2), Prototype 3 (GSP3), Gelesis100,or Gelesis200
        in a previous study Administration of investigational products within one(1) month prior to
        Screening Visit Blood transfusion within three (3) months prior to Screening Visit Smoking
        cessation within six(6) months prior to Screening Visit or considering smoking cessation
        during the study Anticipated surgical intervention during the study period Known Type 1
        Diabetes History of eating disorders including binge eating (except for mild binge
        eating)or emesis ≥2/week from any cause Weight change &gt;3% within three(3) months prior to
        and during the Screening period Supine systolic blood pressure (SBP) &gt;160 millimeters of
        mercury (mmHg)and/or supine diastolic blood pressure(DBP) &gt;95mmHg Angina, coronary bypass,
        or myocardial infarction within six(6)months prior to Screening Visit History of swallowing
        disorders Esophageal anatomic abnormalities (e.g., webs, diverticuli, rings)•History of
        gastroesophageal reflux disease History of gastric or duodenal ulcer History of
        gastroparesis(e.g., chronic nausea, vomiting≥2 occurrences per week, heartburn, etc.)
        History of gastric bypass or any other gastric surgery History of small bowel resection
        (except if related to appendectomy) History of intestinal stricture (e.g., Crohn's disease)
        History of intestinal obstruction or high risk of intestinal obstruction,including
        suspected small bowel adhesions History of abdominal radiation treatment History of
        pancreatitis within the past 12 months History of malabsorption Laxative users, except
        those on stable doses within one (1) month prior to Screening Visit History of hepatitis B
        or C History of human immunodeficiency virus(HIV) History of cancer within the past five(5)
        years (except adequately-treated localized basal cell skin cancer or in situuterine
        cervical cancer) Any other clinically significant disease interfering with the assessments
        of Gelesis200 (e.g., disease requiring corrective treatment, potentially leading to study
        discontinuation) Abnormal serum thyroid-stimulating hormone(TSH) HbA1c &gt;8.5% (&gt;69 mmol/mol)
        Serum low-density lipoprotein (LDL) cholesterol≥160mg/dL (≥4.15mmol/L) Serum triglycerides
        ≥350 mg/dL (≥3.96mmol/L) Positive test for drugs of abuse in the urine Any relevant
        biochemical abnormality interfering with the assessments of Gelesis200 Anti-obesity
        medications (including herbal preparations) within one(1) month prior to Screening Visit
        Systemic corticosteroids within one (1) month prior to Screening Visit Thyroid hormones or
        preparations within one (1) month prior to Screening Visit [except stable dose of
        replacement therapy for at least two(2) months] TSH suppression therapy for thyroid cancer
        Estrogen within one(1) month prior to Screening Visit [except stable dose of replacement
        therapy or contraceptives for at least one(1) month] Any other medication known to cause
        weight loss or weight gain within one (1) month prior to Screening Visit Antidiabetic
        medications within one (1) month prior to Screening Visit [except stable doses of metformin
        and DPP-4 inhibitors for at least one (1) month in subjects with Type 2 Diabetes] Change in
        medications treating hypertension within one (1) month prior to Screening Visit Change in
        medications treating dyslipidemia within one (1) month prior to Screening Visit Anticipated
        requirement for use of prohibited concomitant medications Any other condition that,in the
        opinion of the Investigator or Sponsor, would interfere with the subject's ability to
        participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diana Peremislov, Ph.D</last_name>
    <phone>612 234 8500</phone>
    <phone_ext>23719</phone_ext>
    <email>d.peremislov@medpace.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SAMCRC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Miller, MD</last_name>
      <phone>713-526-2600</phone>
      <email>sam@samcrc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://gelesis.com/clinical-trials.php</url>
    <description>Gelesis Website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

